Plain-English translation of NCT05094284 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →This trial is testing the BioFreedom Ultra stent, a thin metal tube coated with a heart medication that helps prevent arteries from closing again after they are opened. The stent is designed especially for patients who need heart procedures and cannot take blood thinners for long periods. Earlier research shows this thin stent works as well as or better than older, thicker stents.
Thinner stents are known to work better in heart arteries because they allow blood to flow more naturally and are less likely to cause the artery to narrow again. This trial aims to confirm that the medication works safely and effectively in real-world patients in Hong Kong.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the BioFreedom Ultra stent as part of your standard heart procedure to open your blocked artery. The stent placement is done during a catheterization procedure, similar to standard care. After the procedure, you will need to take two blood-thinning medications for one month, then continue with one medication. The hospital will track your health and recovery over time as part of this registry study.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Hong Kong
Enrollment target
~300 participants
Started
October 2021
Primary completion
April 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Daniel Xu
Chinese University of Hong Kong
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.